RXRX vs SNA · rev $14.1M vs P/E 17, rev $2.64B
Recursion Pharmaceuticals Inc (RXRX) versus Snap-On Inc (SNA) — a side-by-side from cached financials, not a winner call.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Snap-On Inc (SNA) is a tools & accessories company listed on US.
Latest reported RXRX revenue for 2026-06-30 was $14.1M. Net income was -$248.5M. RXRX currently screens at market cap $1.75B.
Latest reported SNA revenue for 2026-07-04 was $2.64B. Net income was $507.6M. SNA currently screens at market cap $16.82B and trailing P/E 16.8.
RXRX currently screens at market cap $1.75B. SNA currently screens at market cap $16.82B and trailing P/E 16.8.
Not investment advice. Open the RXRX and SNA stock pages for the full models.
Not investment advice.